Prof Michael Green
Honorary (Professorial Fellow)
Department of Medicine
65 Scholarly works
0 Projects
HIGHLIGHTS
2022
Journal article
Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer
DOI: 10.1016/j.clbc.2022.08.0112022
Journal article
Oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe, chronic cancer pain: Challenges in the context of hepatic impairment
DOI: 10.1111/ajco.135612016
Journal article
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): An open-label randomised, controlled trial
DOI: 10.1093/annonc/mdw0552016
Journal article
A survey of manufacturing and handling practices for monoclonal antibodies by pharmacy, nursing and medical personnel.
DOI: 10.1177/10781552145591132016
Journal article
A review of the evidence for occupational exposure risks to novel anticancer agents - A focus on monoclonal antibodies
DOI: 10.1177/10781552145507292014
Journal article
Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel
DOI: 10.1111/imj.125642014
Journal article
Systemic treatment of HER2 metastatic breast cancer: Clinical conundrums and future perspectives
DOI: 10.1111/ajco.12207
RECENT SCHOLARLY WORKS
2014
Journal article
Systemic treatment of HER2-positive metastatic breast cancer: A systematic review
DOI: 10.1111/ajco.122062013
Journal article
Prevention of chemotherapy-induced neutropenia with pegfilgrastim: Pharmacokinetics and patient outcomes
DOI: 10.1159/0003456262009
Journal article
Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer
DOI: 10.1093/annonc/mdp202